9 November 2020 - AFT Pharmaceuticals today announces it has received a US FDA complete response letter covering its application for the approval of a tablet version of its Maxigesic pain relief medication.

In the letter, the US regulator said an FDA Good Manufacturing Practice inspection of the tablet production facilities – delayed due to COVID-19 related travel disruptions – was the “only deficiency” with AFT’s application.

Read AFT Pharmaceuticals press release